Zobrazeno 1 - 10
of 746
pro vyhledávání: '"Patricia A. Russo"'
Autor:
April F. Mohanty, Emily B. Levitan, Jordan B. King, John A. Dodson, Orly Vardeny, James Cook, Jennifer S. Herrick, Tao He, Olga V. Patterson, Patrick R. Alba, Patricia A. Russo, Engels N. Obi, Michelle E. Choi, James C. Fang, Adam P. Bress
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 20 (2021)
Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Our objective was to describe the sac
Externí odkaz:
https://doaj.org/article/b3e4d96313984c458e4300e40728aa41
Autor:
T.R. Jeffry Evans, Maurizio Voi, Shruti Agrawal, Prashni Paliwal, Valerie G. Brunton, Jeffrey A. Morgan, Ding Wang, Iain R.J. MacPherson, Patricia Lo Russo, George D. Demetri
Supplementary Data from Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e06c2f09e172de59a9655afbe26c21e
https://doi.org/10.1158/1078-0432.22440253
https://doi.org/10.1158/1078-0432.22440253
Autor:
T.R. Jeffry Evans, Maurizio Voi, Shruti Agrawal, Prashni Paliwal, Valerie G. Brunton, Jeffrey A. Morgan, Ding Wang, Iain R.J. MacPherson, Patricia Lo Russo, George D. Demetri
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists.Experimental Desi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::735eef4e2da338a45ef9202bee0418c9
https://doi.org/10.1158/1078-0432.c.6517603
https://doi.org/10.1158/1078-0432.c.6517603
Autor:
Jose Russo, Thomas R. Sutter, Irma H. Russo, Patricia A. Russo, Shirlean Goodwin, Sandra V. Fernandez, Yong Huang
Supplementary Figure 1 from Epithelial to Mesenchymal Transition in Human Breast Epithelial Cells Transformed by 17β-Estradiol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::383110ce0ccc2ae76ef9e3fcb6722632
https://doi.org/10.1158/0008-5472.22371333
https://doi.org/10.1158/0008-5472.22371333
Autor:
Jose Russo, Thomas R. Sutter, Irma H. Russo, Patricia A. Russo, Shirlean Goodwin, Sandra V. Fernandez, Yong Huang
The estrogen dependence of breast cancer has long been recognized; however, the role of 17β-estradiol (E2) in cancer initiation was not known until we showed that it induces complete neoplastic transformation of the human breast epithelial cells MCF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d24cfcf71c5b92789da93bd50a56cc1
https://doi.org/10.1158/0008-5472.c.6496743
https://doi.org/10.1158/0008-5472.c.6496743
Autor:
Jose Russo, Thomas R. Sutter, Irma H. Russo, Patricia A. Russo, Shirlean Goodwin, Sandra V. Fernandez, Yong Huang
Supplementary Figure 2 from Epithelial to Mesenchymal Transition in Human Breast Epithelial Cells Transformed by 17β-Estradiol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8dc9f7ca57e07d9d8495060c4093465
https://doi.org/10.1158/0008-5472.22371330.v1
https://doi.org/10.1158/0008-5472.22371330.v1
Autor:
Jose Russo, Thomas R. Sutter, Irma H. Russo, Patricia A. Russo, Shirlean Goodwin, Sandra V. Fernandez, Yong Huang
Supplementary Figure 3 from Epithelial to Mesenchymal Transition in Human Breast Epithelial Cells Transformed by 17β-Estradiol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2893e48cc7525d470b135973e187d3e9
https://doi.org/10.1158/0008-5472.22371327.v1
https://doi.org/10.1158/0008-5472.22371327.v1
Autor:
Álvaro Vílchez-Cózar, Rosario M.P. Colodrero, Montse Bazaga-García, David Marrero-López, Sayed M. El-refaei, Patricia A. Russo, Nicola Pinna, Pascual Olivera-Pastor, Aurelio Cabeza Díaz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e4f3ea20193294775032316c8b63aa6
https://doi.org/10.2139/ssrn.4395102
https://doi.org/10.2139/ssrn.4395102
Autor:
Kristen Johnson, Helen M Trenz, Patricia A. Russo, Miriam G. Cisternas, Lauren Bartolome, Erin Hulbert, Vikram Patel, Bret Gitar
Publikováno v:
Current Medical Research and Opinion. 37:597-604
The objective of this study was to describe and compare health care resource utilization (HCRU) and disease modifying treatment (DMT) use among US adults65 years with multiple sclerosis (MS), across commercial and Medicare Advantage plans.Medical and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed92804878a2c9cff0dd92768e23ee39
https://doi.org/10.1080/03007995.2021.1885367
https://doi.org/10.1080/03007995.2021.1885367
Autor:
Patricia A. Russo, Adam P. Bress, Jennifer S. Herrick, John A. Dodson, Olga V. Patterson, James Cook, Engels N. Obi, Tao He, Jordan B. King, James C. Fang, April F. Mohanty, Emily B. Levitan, Patrick R. Alba, Michelle Choi, Orly Vardeny
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Our objective was to describe the sac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69df28aaec81f60f48e4ad75bc1d7286
https://doi.org/10.1161/jaha.120.020474
https://doi.org/10.1161/jaha.120.020474